A Phase 3, Placebo-controlled, Randomized, Observer-blinded Study to Evaluate the Efficacy, Safety, and Tolerability of a Clostridium Difficile Vaccine In Adults 50 Years of Age and Older
A pilot study for Allergan's intravenous antibiotic, Dalvance® (dalbavancin), administered every 14 days for the treatment of Septic Arthritis (2 infusions) and / or Osteomyelitis (3 infusions)
B3451002 - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate The Safety and Efficacy of Staphylococcus Aureus 4-Antigen Vaccine (SA4Ag) in Adults Undergoing Elective Posterior Instrumented Lumbar Spinal Fusion Procedures.
A Study to evaluate a Staphylococcus aureus vaccine in patients undergoing elective posterior instrumented lumbar spinal fusion procedures.
Background: Reports of methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (S. aureus) infections in the United States (U.S.) have become commonplace and are well-known to patients, providers, and healthcare administrators. Many researchers have described this major health problem as one of epidemic proportion because of the scope and magnitude of these infections in the U.S. The incidence of MRSA and S. aureus infections has been a burden on the United States’ healthcare system. Although recent MRSA infection rates have seen a slight decline, S. aureus rates have been stable. Prior to the recent slight MRSA decline, hospitalizations for MRSA infections increased 119% from 1999 to 2005. An astounding 16% of all infections in the US are from S. aureus, and roughly 18% are related to surgical site infections. Despite the best known infection control mechanisms, MRSA and S. aureus will continue to be a high focal point for the healthcare community.
The evolution of vaccinations has proven to be an essential part of population health that positively impacts health outcomes and reduces healthcare related expenses. CARE-ID is one of 55 centers in the world evaluating a S. aureus vaccine in individuals undergoing elective posterior instrumented lumbar spinal fusion procedures. The potential use of a preventative S. aureus vaccine in patients undergoing elective surgery would be a major accomplishment in medicine.
Read More at PMLive
Read More at Strive Study
Closed to Enrollment
201585 / ATLAS, A Phase III, randomized, multicenter, parallel-group, non-inferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir, plus long-acting rilpivirine from current INI- NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed
Read More at Healio
AC-061A302, Prospective, multi-center, double-blind, double dummy, randomized, parallel group, group sequential, active controlled phase 3 study to compare the efficacy, tolerability and safety of a 10-day oral administration of cadazolid 250 mg twice daily versus vancomycin 125 mg four times daily in subjects with Clostridium difficile-associated diarrhea (CDAD)
Read More at Actelion
Read More at CDC
GS-US-366-1992, A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/ Rilpivirine/Tenofovir Alafenamide (F/R/TAF) prior to LDV/SOF HCV Treatment, the HIV/HCV Co-STARs study (Co-infection treatment with Single Tablet Antiviral Regimens)
Read More at Medscape
Read More at Healio
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults Read More
A Phase 3 Randomized, Open-Label Study to Evaluate Switching from Regimens Consisting of Ritonavir-boosted Darunavir or Atazanavir plus either Emtricitabine/Tenofovir (FTC/TDF) Fixed-Dose Combination (FDC) or Abacavir/3TC (ABC/3TC) FDC to a Fixed Dose Combination (FDC) of GS-9883/F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed Read More
GS-US-141-1475 A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment –Naive Adults
GS-US-366-1160 A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emitricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects.
A Phase 3b, Radomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF).
A Phase IIb, Dose Ranging Study of Oral GSK1265744 in Combination with Nuceloside Reverse Transcriptase Inhibitors for Induction of HIV-1 Virologic Suppression followed by an Evaluation of Maintenance of Virologic Suppression when oral GSK1265744 is Combined with Oral Rilpivirine in HIV-1 Infected, Antiretroviral Therapy Naïve Adult Subjects.